Neurology

Your Article Summary

See Latest Articles

Guillain–Barre syndrome: update on immunobiology and treatment
Expert Review of Neurotherapeutics, 10/06/09

Kaida K et al. – In the future many kinds of drug candidates that inhibit activation of the complement system at various stages will be used in models of autoimmune neuropathy, in future applied to clinical trials for GBS and its variants. Complement–independent blockade of voltage–gated calcium channels or the apoptotic mechanism of neurons should also be considered. The pathogenic effect of antiganglioside antibody depends upon the local glycolipid environment in the nerve membrane as well as the antibody specificity.

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Outcome of intracerebral haemorrhage patients pre-treated with statins
European Journal of Neurology, 11/17/09

See All of Neuro/Psych pharmacology

Today in Neuropathy/Myopathy...keeping you current

Receive free subspecialty "5-minute updates" via email

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09

Accuracy of Monofilament Testing to Diagnose Peripheral Neuropathy: A Systematic Review
Annals of Family Medicine, 11/10/09

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial
The Lancet, 10/13/09

See All of Neuropathy/Myopathy